Primary Target definition

Primary Target as used herein is any target specified by Sunesis other than CDK2, CDK7 or CDK9. For clarity, if a particular compound that is not a Licensed Compound exhibits activity with an IC50 < [*] against any of CXX0, XXX0 or CDK9, it is a Competitive Compound. Further, if a particular compound that is not a Licensed Compound exhibits activity with an IC50 > [*] against each of CDK2, CDK7 and CDK9, it is not a Competitive Compound. Alternately, by way of example, if a particular compound that is not a Licensed Compound exhibits activity with an IC50 > [*] against both CDK2 and CDK7, but exhibits activity with an IC50 = [*] against CDK9, it is a Competitive Compound unless it also exhibits activity with an IC50 < [*] against one or more Primary Target(s). For the purposes of determining whether a particular compound is a Competitive Compound, activity against any Primary Target shall be measured in an industry standard assay for such Primary Target, or if no such industry standard exists for a particular Primary Target, then the measurement will be made in the assay then used internally by Sunesis for such Primary Target.
Sample 1
Primary Target is defined in Section 2.7.1(b).
Sample 1
Primary Target means, with respect to a given Primary Campaign, the Collaboration Druggable/LDD Target designated as the Primary Target from such Primary Campaign by BMS pursuant to Section 2.5.7; but excluding all Excluded Targets.
Sample 1

Examples of Primary Target in a sentence

  • Primary Conditions versus Secondary Conditions In screening for the Primary Target Conditions/Disorders (see table on page 14) it is likely that secondary conditions/disorders will be detected.

  • The date that is six (6) consecutive months immediately after the Primary Target Closing Date.

  • Initiator Target Response Master on Primary Target on Primary Bridge does not respond.

  • If the Closing does not occur by the Primary Target Closing Date solely by reason of a pending Injunction Preventing Closing, then, provided that CSU has diligently and in good faith taken reasonable steps to cause the dissolution or vacation of the Injunction Preventing Closing, the Closing is automatically extended to not later than the First Extended Closing Date.

  • Master on Primary Target on Secondary Bridge asserts P_DEVSEL#, terminates the cycle normally if it is able to be posted, otherwise return with a retry.

  • Master on Primary Target not on Primary nor Secondary Port Bridge does not respond and the cycle will terminate as master abort.

  • The vaccine will cause immunity in about 90% of individuals but is ineffective against one stereotype of meningococcus which causes about 30% of the cases.

  • For every Journey, we define the Primary Target as the stay (outside home) with the longest dwell time.

  • If the Closing has not occurred by the Primary Target Closing Date, the City shall prepare and deliver to CSU within fifteen (15) Business Days after the Primary Target Closing Date a draft of the CSU New Lease based on and consistent with the terms of the CSU New Lease Summary.

  • If the Closing has not occurred on or before the Primary Target Closing Date, the Parties shall sign and deliver to each other, outside of the Escrow, the CSU New Lease on or before fifteen (15) Business Days after the receipt by CSU of the draft of the CSU New Lease from the City, assuming that the CSU New Lease has been completed and has received the City’s and CSU’s necessary approval.


More Definitions of Primary Target

Primary Target means the protein, including all its isoforms, containing the epitope for which a Product has highest binding affinity.
Sample 1
Primary Target means TNF[*]. For such purposes, “TNF[*]” shall have the meaning defined in Exhibit 1.22.
Sample 1
Primary Target means CD19 Target [***].
Sample 1

Related to Primary Target

  • Soft Target means a target that will suffer minimum damage and cause minimum damage to the subject vehicle in the event of a collision.

  • KPI Target means the acceptable performance level for a KPI as set out in each KPI;

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • M2 Target Amount With respect to any Distribution Date, an amount equal to the lesser of (a) the product of (i) 65.70% minus the Additional Required Enhancement Percentage and (ii) the Pool Balance for such Distribution Date determined as of the last day of the related Collection Period and (b) the amount, if any, by which (i) the Pool Balance for such Distribution Date determined as of the last day of the related Collection Period exceeds (ii) 0.50% of the Cut-off Date Balance.

  • Development Candidate means a Collaboration Compound designated by Biogen Idec as a Development Candidate in accordance with Section 2.6.

  • M4 Target Amount With respect to any Distribution Date, an amount equal to the lesser of (a) the product of (i) 95.30% and (ii) the Aggregate Loan Balance for such Distribution Date determined as of the last day of the related Collection Period and (b) the amount, if any, by which (i) the Aggregate Loan Balance for such Distribution Date determined as of the last day of the related Collection Period exceeds (ii) 0.50% of the Cut-off Date Balance.

  • M3 Target Amount With respect to any Distribution Date, an amount equal to the lesser of (a) the product of (i) 85.50% and (ii) the Pool Balance for such Distribution Date and (b) the amount, if any, by which (i) the Pool Balance for such Distribution Date exceeds (ii) 0.50% of the Cut-off Date Balance.

  • M5 Target Amount With respect to any Distribution Date an amount equal to the lesser of (a) the product of (i) 93.30% and (ii) the Aggregate Loan Balance for such Distribution Date determined as of the last day of the related Collection Period and (b) the amount, if any, by which (1) the Aggregate Loan Balance for such Distribution Date determined as of the last day of the related Collection Period exceeds (2) the Overcollateralization Floor.

  • Acquisition Target means any Person becoming a Subsidiary of the Company after the date hereof; any Person that is merged into or consolidated with the Company or any Subsidiary of the Company after the date hereof; or any Person with respect to which all or a substantial part of that Person’s assets are acquired by the Company or any Subsidiary of the Company after the date hereof.

  • M1 Target Amount With respect to any Distribution Date, an amount equal to the lesser of (a) the product of (i) 70.00% and (ii) the Pool Balance for such Distribution Date and (b) the amount, if any, by which (i) the Pool Balance for such Distribution Date exceeds (ii) 0.50% of the Cut-off Date Balance.

  • Performance Target means the level of performance expected of the HSP in respect of a Performance Indicator or a Service Volume. “person or entity” includes any individual and any corporation, partnership, firm, joint venture or other single or collective form of organization under which business may be conducted.

  • Over-Riding Nomination Criteria means the criteria set out in clause 4.2.

  • Development Milestone Event has the meaning set forth in Section 7.1.

  • Product Candidate means any pharmaceutical product developed, manufactured and/or tested by or on behalf of the Company that has not received a Regulatory Authorization for commercial distribution other than in connection with pre-clinical or clinical trials.

  • Alternative nicotine product means any vaping product, whether or not it includes nicotine, including electronic smoking devices, that can be ingested into the body by chewing, smoking, absorbing, dissolving, inhaling, or by any other means. ‘Alternative nicotine product’ does not include:

  • Licensed Compound means [***].

  • POC (Proof of Concept) means testing the Software for evaluation purposes.

  • Valid write-in candidate means a candidate who has qualified as a write-in

  • Senior Target Amount With respect to each Distribution Date, an amount equal to the lesser of (a) the product of (i) 77.30% and (ii) the Aggregate Loan Balance for such Distribution Date determined as of the last day of the related Collection Period and (b) the amount, if any, by which (i) the Aggregate Loan Balance for such Distribution Date determined as of the last day of the Collection Period exceeds (ii) 0.50% of the Cut-off Date Balance.

  • EBITDA Target means the Company's projected earnings before interest, taxes, one-time transition expenses, non-cash compensation expense charges, depreciation and amortization, as contained in the Company's budget for the Applicable Period and which is approved by the Board (without reference to any adjustments or revision, upwards or downwards, to such projected earnings which are subsequently approved by the Board as part of any subsequent revision to such budget), and (ii) the term "Financial Results" shall mean the Company's EBITDA calculated by reference to the Company's financial statements for the Applicable Period as filed with the Securities and Exchange Commission (the "SEC").

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Design Criteria Package means concise, performance-oriented drawings or specifications for a public construction project. The purpose of the Design Criteria Package is to furnish sufficient information to permit Design-Build Firms to prepare a bid or a response to the District’s Request for Proposals, or to permit the District to enter into a negotiated Design- Build Contract. The Design Criteria Package must specify performance- based criteria for the public construction project, including the legal description of the site, survey information concerning the site, interior space requirements, material quality standards, schematic layouts and conceptual design criteria of the project, cost or budget estimates, design and construction schedules, site development requirements, provisions for utilities, stormwater retention and disposal, and parking requirements applicable to the project. Design Criteria Packages shall require firms to submit information regarding the qualifications, availability, and past work of the firms, including the partners and members thereof.

  • Minor source baseline date means the earliest date after the trigger date on which a major stationary source or a major modification subject to 40 CFR 52.21 or to regulations approved pursuant to 40 CFR 51.166 submits a complete application under the relevant regulations. The trigger date is: